about
Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase.Reversible epigenetic regulation of 14-3-3σ expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1.Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression.Spectrin domain of eukaryotic initiation factor 3a is the docking site for formation of the a:b:i:g subcomplex.Determinants of 14-3-3σ protein dimerization and function in drug and radiation resistance.FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1EIF3i promotes colon oncogenesis by regulating COX-2 protein synthesis and β-catenin activation.Human ABCG2: structure, function, and its role in multidrug resistance.Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments.A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion.Drugging the "undruggable" DNA-binding domain of STAT3APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation.Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2.eIF3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response.Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugsCC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance
P50
Q30589786-D2BD85F0-DFBF-4052-AAE2-E158EDD1EAAFQ34360074-B6A95D03-20DA-4B38-896F-0D3BA87163E4Q35013508-12708B03-215B-49B4-8012-2C62B4CC5CEFQ37109577-4196147A-BF59-404F-9D8D-2BFA7FECA450Q37201229-6E6CB093-8B91-41A9-A8F3-F2731B087FA0Q37272059-49363555-890B-47C8-BE63-2B7F1218B593Q37417939-C531033A-512C-4ED4-AC51-B783755A1B43Q37656530-77D90725-1373-419E-8502-40CD2F519A26Q38003156-9106D363-D481-4DBB-9CDD-E7BE9A0D5448Q38147838-F5532BAB-9979-45FC-A0E8-39424F18D230Q39012525-4DC7DACA-D382-4240-B883-943D27CF0D7DQ42317569-5A300826-7354-4E77-9D0A-6B7D965EF811Q47151712-F356A67A-7C57-47C4-8B2D-98751236D486Q49886235-B74A4FE4-8AF3-4031-90E0-8BB474A5BEC4Q51191211-1E607D9B-1A24-4F3C-8767-B3F302FF5358Q51334042-E4B1FB64-9E84-4727-82A5-07F11F0618B0Q52681396-E02EF23E-1158-4595-ACD1-7A8FC9031D52Q83871364-2288CCF9-8097-43DD-92D0-71C7ED192145Q89187548-7AE5DD9B-5DB4-4D63-AEB6-95C6707E8801Q91259124-95B394D0-4227-4336-AE02-137E8B9E9021Q92912154-ED3E936C-73CC-44A4-BABA-B87FD6CD7AB4
P50
description
investigador
@es
researcher
@en
name
Jian-Ting Zhang
@en
type
label
Jian-Ting Zhang
@en
prefLabel
Jian-Ting Zhang
@en
P31
P496
0000-0002-2803-9914